サマリー

エグゼクティブサマリー

多発性硬化症の世界市場は、2020年には260億1千万米ドルと推定されます。治療オプションとしての疾患修飾薬の導入は、世界の多発性硬化症市場の成長を促進する重要な要因となっています。MSの効果的な治療のための革新的なモノクローナル体、免疫調整剤、免疫抑制剤、インターフェロンの開発など、さまざまな技術的進歩が、主要な成長促進要因として作用しています。さらに、世界の多発性硬化症市場の成長は、経口薬への嗜好のシフトによってもたらされています。また、パイプライン医薬品の増加も、予測期間中に市場拡大の有利な機会を提供すると予想されます。

多発性硬化症市場の拡大は、政府機関や非政府組織によって奨励されています。政府や非政府組織は、多発性硬化症患者の生活の質を向上させるためのさまざまな取り組みやプログラムを支援しています（MS: Quality of Life）。

多発性硬化症の世界市場規模は、多くの大手製薬会社がこの免疫疾患治療のための革新的で効果的な治療法を発見するために臨床試験を実施していることから、今後牽引力を増すと見られています。また、多発性硬化症治療のための臨床試験は、複数の製薬会社によって実施されています。企業は、この症状に苦しむ患者のために、多発性硬化症の放射線治療における新薬の創出に取り組んでおり、これが市場の成長をさらに後押ししています。



報告書の範囲

- 本レポートでは、多発性硬化症市場の過去期間2016年～2020年と予測期間2021年～2026年について分析しています。

- 当レポートでは、多発性硬化症市場を金額（百万米ドル）別に分析しています。

- 多発性硬化症市場の薬効分類（免疫調節薬、免疫抑制薬、インターフェロン、その他）を分析しています。

- 多発性硬化症の市場を投与経路別（経口、注射、点滴）に分析しています。

- 多発性硬化症市場の流通チャネル（病院薬局、小売薬局、オンライン薬局）を分析したレポートです。

- 世界の多発性硬化症市場を流通チャネル別（病院薬局、小売薬局、オンライン薬局）に分析したレポートです。

- 市場は地域別（北米、欧州、アジア太平洋、LAMEA）に分析されています。国別（米国、カナダ、ドイツ、英国、フランス、イタリア、中国、日本、インド、韓国）に分析されています。

- 本レポートでは、地域別、薬物クラス別、投与経路別、流通チャネル別など、市場の魅力に関するフレームワークを通じて、主要な洞察を提示しています。

- また、業界の主な機会、トレンド、ドライバー、課題についても分析されています。

- 本レポートでは、競合他社の開発状況、戦略、パイプライン、新製品開発などを追跡しています。

主な対象読者

- 医療・製薬企業

- コンサルティング・アドバイザリーファーム

- 政府・政策担当者

- 規制当局

ページTOPに戻る

目次

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Multiple Sclerosis Market: Product Outlook

4. Global Multiple Sclerosis Market: Sizing and Forecast

4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026

4.2 Impact of COVID-19 on Global Multiple Sclerosis Market

5. Global Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel

5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class

5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)

5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)

5.1.3 Interferons - Market Size and Forecast (2016-2026)

5.1.4 Others - Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration

5.2.1 Oral - Market Size and Forecast (2016-2026)

5.2.2 Injectable - Market Size and Forecast (2016-2026)

5.2.3 Intravenous - Market Size and Forecast (2016-2026)

5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel

5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)

5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)

5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)

6. Global Multiple Sclerosis Market: Regional Analysis

6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region

7. North America Multiple Sclerosis Market: An Analysis (2016-2026)

7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)

7.2 North America Multiple Sclerosis Market - Prominent Companies

7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)

7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)

7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

7.6 North America Multiple Sclerosis Market: Country Analysis

7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026

7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country

7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

8. Europe Multiple Sclerosis Market: An Analysis (2016-2026)

8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)

8.2 Europe Multiple Sclerosis Market - Prominent Companies

8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)

8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)

8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

8.6 Europe Multiple Sclerosis Market: Country Analysis

8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026

8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country

8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

9. Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)

9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies

9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)

9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)

9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis

9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026

9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country

9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

911 Japan Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value

9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)

10. Global Multiple Sclerosis Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026

11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026

11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026

11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026

12. Competitive Landscape

12.1 Product Pipeline of Leading Multiple Sclerosis Companies

12.2 Market Share Analysis

13. Company Analysis

13.1 Bristol-Myers Squibb

13.2 F. Hoffman-La Roche, Ltd.

13.3 Pfizer Inc.

13.4 GlaxoSmithKline

13.5 Novartis AG

13.6 Teva Pharmaceuticals Industries Limited

13.7 BAYER AG

13.8 Biogen

13.9 EMD Sereno

13.10 NervGen Pharma



List of Figures

Figure 1: Global Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)

Figure 3: Global Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 4: World Population 65 Years & Above (% of Total), 2015-2019

Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)

Figure 7: Global Multiple Sclerosis Market- By Drug Class Market Share, 2020 & 2026

Figure 8: Global Multiple Sclerosis Market- By Immunomodulators, By Value (USD Million), 2016-2026

Figure 9: Global Multiple Sclerosis Market- By Immunosuppressants, By Value (USD Million), 2016-2026

Figure 10: Global Multiple Sclerosis Market- By Interferons, By Value (USD Million), 2016-2026

Figure 11: Global Multiple Sclerosis Market- By Others, By Value (USD Million), 2016-2026

Figure 12: Global Multiple Sclerosis Market- By Route of Administration Market Share, 2020 & 2026

Figure 13: Global Multiple Sclerosis Market- By Oral, By Value (USD Million), 2016-2026

Figure 14: Global Multiple Sclerosis Market- By Injectable, By Value (USD Million), 2016-2026

Figure 15: Global Multiple Sclerosis Market- By Intravenous, By Value (USD Million), 2016-2026

Figure 16: Global Multiple Sclerosis Market- By Distribution Channel Market Share, 2020 & 2026

Figure 17: Global Multiple Sclerosis Market- By Hospital Pharmacy, By Value (USD Million), 2016-2026

Figure 18: Global Multiple Sclerosis Market- By Retail Pharmacy, By Value (USD Million), 2016-2026

Figure 19: Global Multiple Sclerosis Market- By Online Pharmacy, By Value (USD Million), 2016-2026

Figure 20: Global Multiple Sclerosis Market- By Region Market Share, 2020 & 2026

Figure 21: North America Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 22: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 23: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)

Figure 24: North America Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 25: North America Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 26: North America Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 27: North America Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 28: Market Opportunity Chart of North America Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)

Figure 29: North America Multiple Sclerosis Market- By Country Market Share, 2020 & 2026

Figure 30: United States Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 31: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 32: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 33: United State Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 34: United States Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 35: United States Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 36: United States Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 37: Canada Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 38: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 40: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 41: Canada Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 42: Canada Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 43: Canada Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 44: Europe Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 45: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 46: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 47: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 48: Europe Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 49: Europe Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 50: Europe Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 51: Market Opportunity Chart of Europe Multiple Sclerosis Market- By Country, By Value (Year 2016-2026)

Figure 52: Europe Multiple Sclerosis Market- By Country Market Share, 2020 & 2026

Figure 53: Germany Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 54: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 55: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 56: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 57: Germany Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 58: Germany Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 59: Germany Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 60: United Kingdom Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 61: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 62: United Kingdom Number of people with MS (per 100,000 people), 2017

Figure 63: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 64: United Kingdom Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 65: United Kingdom Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 66: United Kingdom Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 67: France Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 68: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 69: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 70: France Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 71: France Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 72: France Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 73: France Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 74: Italy Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 75: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 76: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 77: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 78: Italy Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 79: Italy Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 80: Italy Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 81: Asia Pacific Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 82: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 83: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 84: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 85: Asia Pacific Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 86: Asia Pacific Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 87: Asia Pacific Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 88: Market Opportunity Chart of APAC Multiple Sclerosis Market- By Country, By Value (Year-2026)

Figure 89: APAC Multiple Sclerosis Market- By Country Market Share, 2020 & 2026

Figure 90: China Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 91: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 92: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 93: China Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 94: China Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 95: China Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 96: China Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 97: Japan Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 98: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 99: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)

Figure 100: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 101: Japan Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 102: Japan Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 103: Japan Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 104: India Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 105: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 106: e-pharmacy market in India (USD million)

Figure 107: India Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 108: India Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 109: India Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 110: India Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 111: South Korea Multiple Sclerosis Market Size, By Value, 2016-2026 (USD Million)

Figure 112: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)

Figure 113: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)

Figure 114: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)

Figure 115: South Korea Multiple Sclerosis Market - By Drug Class, By Value (USD Million), 2016-2026

Figure 116: South Korea Multiple Sclerosis Market - By Route of Administration, By Value (USD Million), 2016-2026

Figure 117: South Korea Multiple Sclerosis Market - By Distribution Channel, By Value (USD Million), 2016-2026

Figure 118: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Drug Class (Year-2016-2026)

Figure 119: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Route of Administration (Year 2016-2026)

Figure 120: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Distribution Channel (Year 2016-2026)

Figure 121: Market Attractiveness Chart of Global Multiple Sclerosis Market- By Region (Year 2016-2026)

Figure 122: Global Multiple Sclerosis company market share (%), 2020

Figure 123: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)

Figure 124: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)

Figure 125: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020

Figure 126: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020

Figure 127: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 128: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)

Figure 129: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020

Figure 130: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 131: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020

Figure 132: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020

Figure 133: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020

Figure 134: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020

Figure 135: GlaxoSmithKline Gross Profit (USD Million), 2016-2020

Figure 136: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020

Figure 137: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020

Figure 138: Novartis Annual Sales Revenue (USD Million), 2016-2020

Figure 139: Novartis Annual Net Income/Loss (USD Million), 2016-2020

Figure 140: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 141: Novartis Sales Revenue Split, By Geography Segment (%), FY2020

Figure 142: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)

Figure 143: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)

Figure 144: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020

Figure 145: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020

Figure 146: Bayer Group Sales Revenues, 2016-2020 (USD Million)

Figure 147: Bayer Group Net Profit, 2016-2020 (USD Million)

Figure 148: Bayer Group, By Business Segment (%), FY2020

Figure 149: Bayer Group, By Geographical Segment (%), FY2020

Figure 150: Biogen Sales Revenues, 2016-2020 (USD Million)

Figure 151: Biogen Net Profit, 2016-2020 (USD Million)

Figure 152: Biogen, By Business Segment (%), FY2020

Figure 153: Biogen, By Geographical Segment (%), FY2020

List of Tables

Table A Product Pipeline of Leading Multiple Sclerosis Companies

Table B Product Pipeline of Leading Multiple Sclerosis Companies

Table C Product Pipeline of Leading Multiple Sclerosis Companies - NervGen Pharma